Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Reckitt Launches Catalyst: A $13.3 Million Social Impact Investment Program in the US

Reckitt, the UK-based company known for brands like Lysol and Mucinex, has unveiled a groundbreaking social impact investment initiative called Catalyst in the United States. This five-year program aims to provide $13.3 million in funding and mentorship opportunities to early-stage companies and underrepresented founders, with a focus on delivering health and hygiene solutions to millions of people globally.

NoahAI News9/26/2025

Lilly Halts Phase IIb Obesity Study, Shifting Focus in Competitive Weight Loss Market

Eli Lilly has announced the termination of a Phase IIb clinical trial investigating the combination of bimagrumab and Zepbound (tirzepatide) for weight loss. This decision marks a significant shift in the company's obesity treatment strategy and highlights the intense competition in the rapidly evolving weight loss drug market.

NoahAI News9/25/2025

Capricor Therapeutics Gains New Hope for Duchenne Muscular Dystrophy Treatment

Capricor Therapeutics has received a promising update from the U.S. Food and Drug Administration (FDA) regarding its experimental cell therapy for Duchenne muscular dystrophy (DMD). The company is now preparing to resubmit its application for deramiocel, a potential treatment for Duchenne-related cardiomyopathy, following a constructive meeting with FDA officials.

NoahAI News9/25/2025

Merck KGaA Announces CEO Transition Amid Geopolitical Tensions and Industry Challenges

Merck KGaA, the German healthcare and electronics conglomerate, has announced a significant leadership change as it navigates through a period of geopolitical uncertainty and industry transformation. Belén Garijo, who has led the company through the tumultuous years of the COVID-19 pandemic, will step down from her role as CEO at the end of April 2026, concluding her planned five-year tenure.

NoahAI News9/25/2025

Medtronic's Diabetes Business Prepares for Spinoff as MiniMed, Launches New CGM Products

Medtronic's diabetes business is gearing up for a significant transformation as it prepares to spin off into a standalone company called MiniMed. The move comes as the unit launches new continuous glucose monitoring (CGM) products and continues to innovate in the diabetes care space.

NoahAI News9/25/2025

Moderna Opens UK Vaccine Facility Amid Industry Backlash Against British Life Sciences Policies

Moderna has officially opened its long-anticipated Harwell vaccine production facility in the United Kingdom, reaffirming its commitment to the country even as other pharmaceutical giants retreat from planned investments. The new site, dubbed the Moderna Innovation and Technology Centre, marks a significant milestone in the company's ongoing partnership with the UK government.

NoahAI News9/25/2025

Eli Lilly Halts Phase 2b Obesity Trial for Bimagrumab, Citing Strategic Reasons

Pharmaceutical giant Eli Lilly has unexpectedly withdrawn a phase 2b clinical trial for its obesity treatment bimagrumab, an asset acquired through its $1.9 billion acquisition of Versanis. The company cited "strategic business reasons" for the decision, which comes before any patients were enrolled in the study.

NoahAI News9/25/2025

Heidelberg Pharma Announces Major Restructuring Amid FDA Setback

Heidelberg Pharma, a prominent player in the antibody-drug conjugate (ADC) space, has unveiled a significant restructuring plan following a regulatory setback that has delayed a crucial milestone payment. The German biotech company is set to reduce its workforce by 75% and narrow its research focus in an effort to extend its cash runway into mid-2026.

NoahAI News9/25/2025

Medtronic Expands AI and Robotics Hub, Virtuoso Surgical Receives FDA Breakthrough Designation

Medtronic, a global leader in medical technology, has announced a significant expansion of its London office, doubling both its size and workforce. This move establishes the company's largest global digital center for artificial intelligence (AI) and robotics in surgery. Meanwhile, Virtuoso Surgical has received FDA breakthrough device designation for its robotic system designed for bladder lesion removal.

NoahAI News9/25/2025

Talent Acquisition Leaders in Pharma Shift Focus to Internal Mobility and Workforce Development

In a rapidly evolving pharmaceutical landscape, industry giants are reimagining their approach to talent acquisition and workforce management. Recent developments at Pfizer and Bayer highlight a growing trend towards internal mobility, upskilling, and leveraging technology to retain and develop existing talent.

NoahAI News9/25/2025

Acadia Pharmaceuticals Halts Development of Prader-Willi Syndrome Drug After Phase III Failure

Acadia Pharmaceuticals has announced the discontinuation of its investigational treatment for hyperphagia in Prader-Willi syndrome (PWS) following disappointing results from a late-stage clinical trial. The decision marks a significant setback in the pursuit of effective therapies for this rare neurological condition.

NoahAI News9/25/2025

Sanofi Boosts Venture Arm with $625M Investment, Focusing on Rare Diseases and Neuroscience

Sanofi, the French pharmaceutical giant, has injected $625 million into its venture capital unit, Sanofi Ventures, signaling a strong commitment to early-stage biotechnology and digital health companies. This strategic move, announced on Wednesday, brings the total assets under management for Sanofi Ventures to an impressive $1.4 billion.

NoahAI News9/25/2025

«1...62 63 64...67 »